JAMA Network
About The Study: The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a reduced risk of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations compared with dipeptidyl peptidase 4 inhibitors in adults with type 2 diabetes and active COPD. This may inform prescribing of glucose-lowering medications among patients with type 2 diabetes and active COPD.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
